MILWAUKEE, WI--(Marketwire - June 10, 2010) - Prolitec Inc., a developer of air treatment and air care technologies, announced today the appointment of Dr. Craig A. Kelly as Vice President and Director of Technology Development.
The veteran Johns Hopkins University scientist will also serve as chief of the company’s Aerobiology and Infection Control unit. In this role, Dr. Kelly will lead Prolitec’s research and development of airborne and surface antimicrobial systems designed to kill bacteria and viruses in healthcare facilities, schools, assisted living facilities, commercial aircraft, and other public spaces where the control of infection transmission is an important issue.
“We have long experience working with Dr. Kelly in some of his earlier assignments,” said Richard Weening, CEO of Prolitec. “He is exactly the right person to expand the R&D effort and transform the work into the practical infection control applications so urgently needed by the healthcare system.”
Prior to joining Prolitec, Dr. Kelly spent 10 years as a member of the Senior Professional Staff at Johns Hopkins’ Applied Physics Lab in Baltimore, where he worked on a wide range of projects, including chemical and biological warfare agent decontamination. Most recently, from 2009 to 2010, he served as Acting Program Manager for the laboratory’s Missile Defense Agency Sensors Directorate. He began at the laboratory in 1999, initially working on chemical sensor development.
Dr. Kelly has published 21 peer-reviewed scientific articles and has been awarded three patents. He holds a Ph.D. in Physical Inorganic Chemistry from Bowling Green State University and a B.S. in Chemistry from the State University of New York at Geneseo. Additionally, he completed post-doctoral fellowships at the Brookhaven National Laboratory Chemistry Department, Johns Hopkins’ Department of Chemistry and Johns Hopkins’ Applied Physics Laboratory.
“Infection control is a serious challenge for healthcare, education and several other sectors where harmful bacteria, viruses and fungi pose a threat to humans,” Dr. Kelly noted. “Prolitec has developed new and promising technologies to address these issues. Our objective is to advance them into fully operational systems approved by the relevant regulatory agencies.”
About Prolitec
Prolitec (www.prolitec.com) develops and deploys air treatment and air care technologies, including odor control, ambient scenting, aromatherapy and the use of scent as a medium of communication. Clients include assisted living facilities, hotels, casinos, retailers and other commercial facilities in the U.S. and 46 countries around the world. Prolitec’s Aerobiology and Infection Control unit is developing interior air and surface systems to inhibit disease transmission.
